{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:56:17Z","timestamp":1724367377276},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1186\/s12911-019-0860-6","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:02:32Z","timestamp":1565222552000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparing drug safety of hepatitis C therapies using post-market data"],"prefix":"10.1186","volume":"19","author":[{"given":"Jing","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingcheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason H.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,8]]},"reference":[{"key":"860_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jsps.2014.04.008","volume":"24","author":"TM Alshammari","year":"2016","unstructured":"Alshammari TM. Drug safety: the concept, inception and its importance in patients\u2019 health. Saudi Pharm J. 2016;24:405\u201312.","journal-title":"Saudi Pharm J"},{"key":"860_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","volume":"57","author":"K Martin","year":"2004","unstructured":"Martin K, B\u00e9gaud B, Latry P, et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004;57:86\u201392.","journal-title":"Br J Clin Pharmacol"},{"key":"860_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40264-015-0358-9","volume":"39","author":"L McCormack","year":"2016","unstructured":"McCormack L, Craig Lefebvre R, Bann C, et al. Consumer understanding, preferences, and responses to different versions of drug safety messages in the United States: a randomized controlled trial. Drug Saf. 2016;39:171\u201384.","journal-title":"Drug Saf"},{"key":"860_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1745-6215-13-138","volume":"13","author":"S Singh","year":"2012","unstructured":"Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012;13:138.","journal-title":"Trials"},{"key":"860_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/2229-3485.71852","volume":"1","author":"V Suvarna","year":"2010","unstructured":"Suvarna V. Phase IV of drug development. Perspect Clin Res. 2010;1:57\u201360.","journal-title":"Perspect Clin Res"},{"key":"860_CR6","unstructured":"Food US, Administration D, Others. Questions and answers on FDA\u2019s adverse event reporting system (FAERS). http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatory-Information\/Surveillance\/AdverseDrugEffects . Accessed 12 June 2019."},{"key":"860_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14786440009463897","volume":"50","author":"KX Pearson","year":"1900","unstructured":"Pearson KX. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. The London, Edinburgh, and Dublin philosophical magazine and Journal of Science. 1900;50:157\u201375 Taylor & Francis.","journal-title":"The London, Edinburgh, and Dublin philosophical magazine and Journal of Science"},{"key":"860_CR8","unstructured":"Greenwood PE, Nikulin MS. A guide to chi-squared testing: John Wiley & Sons; 1996."},{"key":"860_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Dumouchel","year":"1999","unstructured":"Dumouchel W. Bayesian data Mining in Large Frequency Tables, with an application to the FDA spontaneous reporting system. Am Stat. 1999;53:177\u201390 Taylor & Francis.","journal-title":"Am Stat"},{"key":"860_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"860_CR11","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350\u20139.","journal-title":"Gut"},{"key":"860_CR12","first-page":"S237","volume":"36","author":"MW Fried","year":"2002","unstructured":"Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237\u201344.","journal-title":"Hepatology"},{"key":"860_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11901-010-0078-7","volume":"10","author":"H Sung","year":"2011","unstructured":"Sung H, Chang M, Saab S. Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepatol Rep. 2011;10:33\u201340. https:\/\/doi.org\/10.1007\/s11901-010-0078-7 .","journal-title":"Curr Hepatol Rep"},{"key":"860_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705\u201314.","journal-title":"Ann Intern Med"},{"issue":"4","key":"860_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/ph3041162","volume":"3","author":"MG Tovey","year":"2010","unstructured":"Tovey MG, Lallemand C. Safety, tolerability, and immunogenicity of interferons. Pharmaceuticals. 2010;3(4):1162\u201386.","journal-title":"Pharmaceuticals."},{"issue":"6","key":"860_CR16","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V96.6.2093","volume":"96","author":"Q Wang","year":"2000","unstructured":"Wang Q, Miyakawa Y, Fox N, Kaushansky K. Interferon-\u03b1 directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood. 2000;96(6):2093\u20139.","journal-title":"Blood."},{"issue":"6","key":"860_CR17","first-page":"423","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-\u03b1 therapy. J Pharm Pharm Sci. 2005 Dec 1;27(6):423.","journal-title":"J Pharm Pharm Sci"},{"key":"860_CR18","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/hep.25556","volume":"55","author":"MM Denniston","year":"2012","unstructured":"Denniston MM, Klevens RM, McQuillan GM, et al. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and nutrition examination survey 2001-2008. Hepatology. 2012;55:1652\u201361.","journal-title":"Hepatology"},{"key":"860_CR19","volume-title":"Hepatitis C FAQs for the public","author":"Center for Disease Control C, Prevention, Others","year":"2016","unstructured":"Center for Disease Control C, Prevention, Others. Hepatitis C FAQs for the public. Atlanta, GA: Division of Viral Hepatitis and National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention; 2016."},{"key":"860_CR20","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda JM, Evans L, Vanguri RS, et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:160026.","journal-title":"Sci Data"},{"key":"860_CR21","doi-asserted-by":"publisher","first-page":"baw036","DOI":"10.1093\/database\/baw036","volume":"2016","author":"Jun Xu","year":"2016","unstructured":"Xu J, Wu Y, Zhang Y, et al. CD-REST: a system for extracting chemical-induced disease relation in literature. Database. 2016;2016. https:\/\/doi.org\/10.1093\/database\/baw036 .","journal-title":"Database"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-019-0860-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12911-019-0860-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-019-0860-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T20:08:11Z","timestamp":1721592491000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-019-0860-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":21,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1186\/s12911-019-0860-6","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"8 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"147"}}